Literature DB >> 15177297

Constitutive production of human leptin by fed-batch culture of recombinant rpoS- Escherichia coli.

Ki Jun Jeong1, Jong Hyun Choi, Won Min Yoo, Ki Chang Keum, Nae Choon Yoo, Sang Yup Lee, Moon-Hee Sung.   

Abstract

High-level production of human leptin by fed-batch culture of recombinant Escherichia coli using constitutive promoter system was investigated. For the constitutive expression of the obese gene encoding human leptin, the strong constitutive HCE promoter cloned from the D-amino acid aminotransferase gene of Geobacillus toebii was used. To develop an optimal host-vector system, several different recombinant E. coli strains were compared for leptin production. In flask cultures, E. coli FMJ123, which is a rpoS mutant strain, showed the highest level of leptin production (41% of total proteins). By comparing the expression levels of leptin in several different rpoS- and rpoS+ strains, it could be concluded that rpoS mutation positively affected constitutive production of leptin. For the large-scale production of human leptin, fed-batch cultures of recombinant E. coli FMJ123 were carried out using three different feeding solutions--chemically defined, yeast extract-containing, and casamino acid-containing feeding solutions. Among these, the use of casamino acid-containing feeding solution allowed production of leptin up to 2.1 g/L, which was 2.1- and 1.8-fold higher than that obtained with chemically defined and yeast extract-contained feeding solutions, respectively. These results suggest that the HCE promoter can be used for the efficient production of leptin, and most likely other recombinant proteins, in a constitutive manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177297     DOI: 10.1016/j.pep.2004.04.007

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  8 in total

1.  Statistical optimization of medium for the production of pyruvate oxidase by the recombinant Escherichia coli.

Authors:  Jie Zhao; Yonghong Wang; Ju Chu; Siliang Zhang; Yingping Zhuang; Zhongyi Yuan
Journal:  J Ind Microbiol Biotechnol       Date:  2008-01-31       Impact factor: 3.346

2.  New constitutive vectors: useful genetic engineering tools for biocatalysis.

Authors:  Youqiang Xu; Fei Tao; Cuiqing Ma; Ping Xu
Journal:  Appl Environ Microbiol       Date:  2013-02-15       Impact factor: 4.792

3.  Influence of Foreign DNA Introduction and Periplasmic Expression of Recombinant Human Interleukin-2 on Hydrogen Peroxide Quantity and Catalase Activity in Escherichia coli.

Authors:  Lena Mahmoudi Azar; Elnaz Mehdizadeh Aghdam; Farrokh Karimi; Babak Haghshenas; Abolfazl Barzegari; Parichehr Yaghmaei; Mohammad Saeid Hejazi
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 4.  Increasing recombinant protein production in Escherichia coli through metabolic and genetic engineering.

Authors:  Hendrik Waegeman; Wim Soetaert
Journal:  J Ind Microbiol Biotechnol       Date:  2011-09-08       Impact factor: 3.346

Review 5.  Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells.

Authors:  Aleš Berlec; Borut Strukelj
Journal:  J Ind Microbiol Biotechnol       Date:  2013-02-06       Impact factor: 3.346

6.  High-yield production of the VP1 structural protein epitope from serotype O foot-and-mouth disease virus in Escherichia coli.

Authors:  Joon-Goo Jung; Yong Jae Lee; Natarajan Velmurugan; Young-Joon Ko; Hyang-Sim Lee; Ki Jun Jeong
Journal:  J Ind Microbiol Biotechnol       Date:  2013-04-26       Impact factor: 3.346

Review 7.  Genome engineering for improved recombinant protein expression in Escherichia coli.

Authors:  Shubhashree Mahalik; Ashish K Sharma; Krishna J Mukherjee
Journal:  Microb Cell Fact       Date:  2014-12-19       Impact factor: 5.328

8.  Effect of membrane fusion protein AdeT1 on the antimicrobial resistance of Escherichia coli.

Authors:  Victoria L Barlow; Shu-Jung Lai; Chia-Yu Chen; Cheng-Han Tsai; Shih-Hsiung Wu; Yu-Hsuan Tsai
Journal:  Sci Rep       Date:  2020-11-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.